Daniele Laszlo

Summary

Affiliation: European Institute of Oncology
Country: Italy

Publications

  1. ncbi request reprint Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
    Giovanni Martinelli
    European Institute of Oncology, Milan, Italy
    Br J Haematol 123:271-7. 2003
  2. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
  3. doi request reprint Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    D Laszlo
    European Institute of Oncology, Milan, Italy
    Int J Surg Pathol 19:417-24. 2011
  4. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia
    D Laszlo
    Department of Haematology, European Institute of Oncology, Milan, Italy
    Clin Lymphoma Myeloma Leuk 11:130-2. 2011
  5. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    Daniele Laszlo
    Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 28:2233-8. 2010
  6. doi request reprint Who should be really considered as a poor mobilizer in the plerixafor era?
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Transfus Apher Sci 47:27-32. 2012
  7. doi request reprint Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
    Paola Bertazzoni
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 51:1485-93. 2010
  8. ncbi request reprint Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy
    Giovanni Martinelli
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1979-83. 2005
  9. ncbi request reprint The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Pathol 206:337-45. 2005
  10. doi request reprint Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Eur J Haematol 88:154-8. 2012

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
    Giovanni Martinelli
    European Institute of Oncology, Milan, Italy
    Br J Haematol 123:271-7. 2003
    ..Based on our preliminary data, the combination of chlorambucil with rituximab seemed to be well tolerated and active. Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials...
  2. ncbi request reprint Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat
    Daniele Laszlo
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Eur J Haematol 72:264-7. 2004
    ....
  3. doi request reprint Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
    D Laszlo
    European Institute of Oncology, Milan, Italy
    Int J Surg Pathol 19:417-24. 2011
    ..Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting...
  4. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia
    D Laszlo
    Department of Haematology, European Institute of Oncology, Milan, Italy
    Clin Lymphoma Myeloma Leuk 11:130-2. 2011
    ..024). The combination of rituximab/cladribine is safe and effective in WM patients requiring treatment. The pharmacogenomic analysis suggests that hCNT1 might be beneficial in predicting clinical response to such a combination treatment...
  5. doi request reprint Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    Daniele Laszlo
    Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 28:2233-8. 2010
    ....
  6. doi request reprint Who should be really considered as a poor mobilizer in the plerixafor era?
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Transfus Apher Sci 47:27-32. 2012
    ..0×10(6) CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients...
  7. doi request reprint Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
    Paola Bertazzoni
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    Leuk Lymphoma 51:1485-93. 2010
    ..The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5% of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL...
  8. ncbi request reprint Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy
    Giovanni Martinelli
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1979-83. 2005
    ....
  9. ncbi request reprint The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    J Pathol 206:337-45. 2005
    ..Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells...
  10. doi request reprint Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
    Giovanna Andreola
    Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
    Eur J Haematol 88:154-8. 2012
    ..0 × 10(6) /kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells...
  11. ncbi request reprint R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma
    Juan Montoro
    Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy Electronic address
    Transfus Apher Sci 50:411-4. 2014
    ..Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events. ..
  12. doi request reprint Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma
    Francesco Lanza
    Section of Hematology and BMT Unit, Cremona Hospital, Cremona, Italy Department of Hematology and Oncological Sciences, Institute of Hematology L and A Seràgnoli, University of Bologna, Bologna, Italy Section of Hematology, University Hospital of Ancona, Ospedali Riuniti, Ancona, Italy Hemato Oncology Unit, Istituto Europeo Oncologico, Milan, Italy Section of Hematology, Reggio Calabria Hospital, Reggio Calabria, Italy Section of Hematology, University Hospital of Bari, Bari, Italy Section of Hematology, Tricase Hospital, Tricase, Italy Section the of Hematology, Rimini Hospital, Rimini, Italy Section of Hematology, University Hospital Ferrarotto, Policlinico Vittorio Emanuele, Catania, Italy Section of Hematology, Humanitas Hospital BMT Unit, S Raffaele Hospital, Milan, Italy Section of Hematology, Hospital Casa Sollievo Sofferenza, Japan
    Transfusion 54:331-9. 2014
    ..We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients...
  13. ncbi request reprint Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index
    Giancarlo Pruneri
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
    Int J Cancer 112:71-7. 2004
    ..Our data suggest that the t(6;14) translocation may be extremely uncommon in FL and that a deregulated expression of cyclin D3, possibly due to epigenetic mechanisms, may be involved in the pathogenesis of high-grade tumors...
  14. doi request reprint Efficacy of photopheresis extracorporeal procedure as single treatment for severe chronic GVHD: a case report
    Federica Gigli
    European Institute of Oncology, Hematoncology Divisione, Milan, Italy Humanitas Cancer Center, Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy Electronic address
    Transfus Apher Sci 49:205-7. 2013
    ..This experience may support the possibility to use only an immunomodulant treatment like ECP for the cGVHD, reducing the risk of complications of prolonged immunosuppressant treatment...
  15. ncbi request reprint Fludarabine combination regimen severely affected peripheral blood stem cell mobilization
    Daniele Laszlo
    Department of Hematoncology, European Institute of Oncology, Milan, Italy
    Acta Haematol 111:228-9. 2004
  16. ncbi request reprint Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: a single institution experience
    Alberto Agazzi
    Hematoncology Division, European Institute of Oncology, Milan, Italy
    J Thromb Thrombolysis 15:109-11. 2003
  17. doi request reprint Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
    Giancarlo Pruneri
    Leuk Res 32:1628-32. 2008